Generic Name: Dolutegravir (50mg) + Emtricitabine (200mg) + Tenofovir Alafenamide (25mg).
Spegra Tablet is a combination medication used in the treatment of HIV-1 infection. This combination of drugs is effective in managing the progression of the virus, enhancing the immune system, and reducing the viral load in the bloodstream.
This medication is typically prescribed as part of an antiretroviral therapy (ART) regimen, which helps manage and control the progression of HIV.
Spegra Tablets contains three Active Ingredients:

• Dolutegravir: It is an integrase strand transfer inhibitor (INSTI) that hinders the replication of the HIV virus by targeting a specific enzyme in the virus.


• Emtricitabine: An NRTI (nucleoside reverse transcriptase inhibitor) that also inhibits HIV replication.


• Tenofovir Alafenamide: Another NRTI that impedes the replication of the HIV virus and is known for its improved safety profile compared to older formulations of tenofovir

This combination medication is primarily used for the treatment of HIV-1 infection in both treatment-na?ve and treatment-experienced individuals. It is an effective and well-tolerated option for managing HIV.

• Customer-Centric Solutions: Parshva Agency focuses on delivering tailored private labeling services on a Peer-to-Peer (P2P) basis to meet the unique needs of each client.
• Regulatory Support: The agency is backed by experienced regulatory experts who ensure full compliance with all industry standards, providing peace of mind to clients.
• State-of-the-Art Manufacturing: Partnered with advanced manufacturing facilities that meet WHO-GMP certifications, Parshva Agency emphasizes the importance of modern production techniques.
• Quality and Efficacy: With WHO-GMP certification, the agency guarantees that its products maintain the highest standards of quality and efficacy.
• Reliability: Parshva Agency is committed to providing safe, reliable, and compliant products that meet stringent regulatory guidelines, fostering trust among clients and stakeholders.